Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 39Terminated 15Unknown 10Recruiting 10Not yet recruiting 3Active not recruiting 2Withdrawn 1No longer available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 2Stomach Neoplasms 1Neoplasm Metastasis 1Metastatic Colorectal Adenocarcinoma 1Advanced Gastric or EGJ Cancer 1

Interventions

Bevacizumab 30pembrolizumab 29Oxaliplatin 28Leucovorin 25Fluorouracil 24Irinotecan 22Cetuximab 22Capecitabine 19Nivolumab 15Specimen Handling 12atezolizumab 11Panitumumab 11Colonoscopy 9Carboplatin 9regorafenib 8Biopsy 8trifluridine tipiracil drug combination 7Trifluridine 7Paclitaxel 7Aspirin 7balstilimab 6Standard of Care 6Cisplatin 6tislelizumab 5encorafenib 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Immunoglobulin G 5Folfox protocol 5Disulfides 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Colorectal Neoplasms × IFL protocol × Clear all
NCT04587128 2026-02-05

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

University of Wisconsin, Madison

Phase 2 Active not recruiting
34 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06106308 2026-01-12

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Cardiff Oncology

Phase 2 Active not recruiting
113 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡